Scra.info

NEWS RELEASE FOR IMMEDIATE RELEASE For More Information Contact: SCRA MUSC Innovation Center, Charleston Welcomes 5th New Tenant: Iverson Genetic Diagnostics, Inc. Iverson Genetic Diagnostics 3rd Annual Shareholders Meeting this Saturday, July 17th, 9:00 a.m. Media welcome to attend open sessions of Meeting More Information about the Shareholders Meeting at the end of this News Release* CHARLESTON, SC– July 14, 2010 – a global leader in applied research and
commercialization, announces today that Iverson Genetic Diagnostics, Inc., ("Iverson Genetics")
is the fifth and latest tenant to move into t at 645
Meeting Street since thein December, 2009.
Iverson Genetics,company, is helping lead the way into the new era of
personalized medicine. The company offers advanced genetic testing to healthcare providers to
promote early disease detection and to help physicians achieve optimal dosing of critical
"Iverson Genetics is committed to providing healthcare providers with state-of-the-art
diagnostics that maintain or improve quality of life," said Dean Sproles, Iverson Genetics' CEO.
"With our commitment to quality, affordability, and rapid turnaround of test results, the
Innovation Center and biotechnology sector in Charleston is a natural fit for Iverson Genetics as
we build our staffing with highly educated life sciences professionals and expand our service
offerings in both the United States and Canada."
According to Iverson Genetics, the Charleston Iverson Laboratory at the SCRA MUSC
Innovation Center will provide genetic testing with 24-hour turnaround capabilities and become
the hub of nationwide Clopidogrel (Plavix™) genetic testing, as well as a support laboratory for
Plavix™ is prescribed by physicians to lower the risk of adverse clotting, especially in those with
implanted stents, thereby reducing the risk of cardiovascular events.
The establishment of its Charleston lab will allow Iverson Genetics to further develop and
expand its genetic diagnostic products and better serve the healthcare market. The Iverson
Genetics lab at the SCRA MUSC Innovation Center is a registerlaboratory (Clinical
"We are proud that Iverson Genetics is establishing their national headquarters at the SCRA
MUSC Innovation Center," said Bill Mahoney, SCRA CEO. "In concert with the Medical
University of South Carolina (MUSC), our academic partner in Charleston to support knowledge
economy development in Charleston and throughout SC, Iverson is a prime example of how
effective public-private partnerships are achieving outstanding knowledge economy
"SC Launch, along with our partners across the state, is pleased to welcome Iverson to the
SCRA MUSC Innovation Center," said Dave McNamara, SC Launch Executive Director.
"Iverson further strengthens the growing bio-med industry in South Carolina."
The SCRA MUSC Charleston Innovation Center, a fully-renovated facility, attracts and supports
start-up companies with wet lab and equipment space, primarily in concert with entrepreneurs
commercializing MUSC research. With this collaboration, SCRA is fulfilling legislative mandates
identified in the Innovation Centers Act focused on the commercialization of new knowledge-
Four start-up companies, all created from technology formed at MUSC, are already
headquartered in the new SCRA MUSC Innovation Center: Immunologix, Microbial Fuel Cell
Technologies, Neurological Testing Services and Vortex Biotechnology Corporation.
Since the start of the SC Launch Program four years ago, SC Launch has assisted, helped form
and/or land more than 230 knowledge-based entities in South Carolina, providing both funding
and services to more than 178. The Program has attracted more than $104 million in add-on,
private equity investment in South Carolina companies. SC Launch is one of over 100 programs
in SCRA's overall operations, which have made a cumulative economic contribution of more
than $13.7B to South Carolina since 1983.
*Iverson Genetic Diagnostics, Inc. will hold their 3rd Annual Shareholders Meeting at 9 am on July 17th in the SCRA MUSC Innovation Center, 645 Meeting Street, Charleston, SC Dean Sproles, CEO, and a graduate of the Citadel will be addressing: 1) The Warfarin Study. 2) How genetic testing is entering into mainstream medicine. 3) The future of genetic Physician's Logic Panels and intellectual properties. Tours of the Iverson lab will be conducted at the conclusion of the meeting at approximately 1:45 p.m. Media is welcome to attend the open sessions of the Shareholders Meeting About Iverson Genetics Diagnostics
Iverson Genetic Diagnostics is a leader in making actionable genetic information readily
available to physicians in everyday practice. The mission of Iverson Genetic Diagnostics is to
provide physicians with clinically relevant gene-based information to optimize therapy and
enhance personal wellness for their patients. Through its gene-based health and treatment
profiles, the company provides physicians with actionable genetic information to optimize clinical
decision-making and patient care. Iverson Genetic Diagnostics is headquartered in the Seattle
suburb of Bothell, Washington where it maintains CLIA and CAP certified genetic testing
laboratories. In addition, the company operates two specialty-specific genetic testing labs
through university relationships in Georgia and South Carolina. For more information, visit
About SCRA
SCRA is a global leader in applied research and commercialization services with its
Headquarters in South Carolina. SCRA collaborates to advance technology, providing
technology-based solutions with assured outcomes to industry and government, with the
help of research universities in SC, the US and around the world.
About SC Launch
SC Launch, an SCRA program, assists entrepreneurial start-up companies with up-front
counseling, seed-funding, and access to a powerful resource network. The SC Launch mission
is to help generate knowledge economy jobs in South Carolina, enhance the state's quality of
life and provide opportunity for all South Carolinians in the new economy.

Transmission of infectious diseases during commercial air travel Alexandra Mangili, Mark A Gendreau Lancet 2005; 365: 989–96 See Comment page 917 Because of the increasing ease and affordability of air travel and mobility of people, airborne, food-borne, vector- Division of Geographic borne, and zoonotic infectious diseases transmitted during commercial air travel are an importa